Ministerio de Industria, Turismo y Comercio LogoMinisterior
 

Biomarcadores para diagnóstico de Demencia

Resultados 61 resultados
LastUpdate Última actualización 20/08/2025 [07:37:00]
pdfxls
Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days
Resultados 1 a 25 de 61 nextPage  

METHOD AND COMPOSITION FOR GENERATING BASAL FOREBRAIN CHOLINERGIC NEURONS (BFCNS)

NºPublicación:  US2025257318A1 14/08/2025
Solicitante: 
NEW YORK STEM CELL FOUND INC [US]
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI [US]
New York Stem Cell Foundation, Inc,
Icahn School of Medicine at Mount Sinai
US_2025257318_A1

Resumen de: US2025257318A1

The invention relates to methods and compositions for developing basal forebrain cholinergic neurons (BFCNs) from stem cells, and in particular, BFCNs having repaired electrophysiological defects relating to one or more mutations in PSEN2, and to the use of such BFCNs in cell-based therapies to treat Alzheimer's disease.

MODIFIED POLYPEPTIDE AND USE THEREOF

NºPublicación:  WO2025166920A1 14/08/2025
Solicitante: 
SHANGHAI LIONRUN BIOMEDICINE TECH CO LTD [CN]
\u4E0A\u6D77\u826F\u6DA6\u751F\u7269\u533B\u836F\u79D1\u6280\u6709\u9650\u516C\u53F8
WO_2025166920_PA

Resumen de: WO2025166920A1

The present invention belongs to the technical field of detection reagents, and relates to a modified polypeptide and the use thereof. The modified β amyloid protein polypeptide comprises peptide fragment I, peptide fragment II, and peptide fragment III located between the peptide fragment I and the peptide fragment II. The peptide fragment I contains a sequence as shown in SEQ ID NO: 9, the peptide fragment II contains a sequence as shown in SEQ ID NO: 18, and the peptide fragment III is composed of non-hydrophobic amino acids. Linker compounds are added between the peptide fragment I and the peptide fragment III, as well as between the peptide fragment II and the peptide fragment III. Compared with the original polypeptide, the modified polypeptide is reduced in terms of synthesis difficulty and cost, and improved in terms of stability. In terms of reaction activity with antibodies, the modified form is consistent with the original polypeptide, is a better raw material form for a calibrator of a diagnostic reagent, and is beneficial to development and wide application of a detection kit.

ANTIBODIES SPECIFIC FOR HYPERPHOSPHORYLATED TAU AND METHODS OF USE THEREOF

NºPublicación:  US2025257124A1 14/08/2025
Solicitante: 
H LUNDBECK AS [DK]
H. Lundbeck A/S
US_2025257124_A1

Resumen de: US2025257124A1

The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.

PROTEIN ANTIGEN COMBINATION FOR DETECTION OF ALZHEIMER'S DISEASE AND APPLICATION THEREOF

NºPublicación:  US2025258184A1 14/08/2025
Solicitante: 
SHANGHAI ZHONGQI BIOTECHNOLOGY CO LTD [CN]
Shanghai Zhongqi Biotechnology Co., Ltd
US_2025258184_A1

Resumen de: US2025258184A1

The present disclosure belongs to the field of biological detection, and particularly relates to a protein antigen combination for detection of Alzheimer's disease (AD) and application thereof. The specific technical solution is as follows: An antigen combination is provided, wherein the antigen combination at least simultaneously includes the following proteins: DOC2A, LGALS1, KDM4D, and ADARB1. The present disclosure provides several new protein antigens and the combination thereof, which can be used for early-screening detection or diagnosis of AD, and are particularly suitable for risk assessment and prediction prior to the onset of AD. Meanwhile, the protein antigens and the combination thereof can distinguish AD from other types of dementia, and can be further prepared into related reagents or kits according to needs.

SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS

NºPublicación:  EP4598923A1 13/08/2025
Solicitante: 
UNIV CALIFORNIA [US]
The Regents of the University of California
US_2024197682_PA

Resumen de: US2024197682A1

A method of inhibiting propagation of protein misfolding associated with a neurological disease, is carried out by contacting an environment populated with a propagating amyloid conformation of a protein (prion) associated with a neurological disease with molecules which binds multiple adjacent sites of the protein assemblies and allowing the molecules to bind multiple cites of the protein assemblies; and thereby impeding propagation of the disease-associated conformation of the protein in the environment. Drug/prion complexes are formed and uses of the drugs in detection and treatment of neurodegenerative diseases are disclosed.

SUBJECT SELECTION FOR 11BETA-HSD1 INHIBITOR TREATMENT

NºPublicación:  EP4599254A1 13/08/2025
Solicitante: 
ACTINOGEN MEDICAL LTD [AU]
Actinogen Medical Limited
CN_120153257_A

Resumen de: AU2023357033A1

The present disclosure generally relates to the surprising discovery that subjects likely to respond to treatment with an 11β-HSD1 inhibitor can be selected for treatment based on a comparison between a baseline level of a tau protein in the subject, and a reference level of the tau protein.

PROTEIN MARKER FOR ASSESSING AND TREATING NEURODEGENERATIVE DISEASES

NºPublicación:  EP4599078A1 13/08/2025
Solicitante: 
UNIV HONG KONG SCIENCE & TECH [HK]
HONG KONG CENTER FOR NEURODEGENERATIVE DISEASES LTD [HK]
The Hong Kong University of Science and Technology,
Hong Kong Center for Neurodegenerative Diseases Limited
CN_120129834_PA

Resumen de: AU2023356443A1

Provided is a protein marker Nell-1, which is present in a person's blood sample in an amount that is correlated with neurodegenerative disorders such as Alzheimer's Disease (AD), Mild Cognitive Impairment (MCI), and Parkinson's Disease (PD). Corresponding diagnostic and treatment methods for these neurodegenerative disorders as well as kits for diagnosing or treating the neurodegenerative disorders are also provided.

アルツハイマー病を判定するためのタンパク質マーカー

NºPublicación:  JP2025118826A 13/08/2025
Solicitante: 
ザ・ホンコン・ユニバーシティー・オブ・サイエンス・アンド・テクノロジー
JP_2025118826_PA

Resumen de: US2023213535A1

The present invention provides protein markers present in a person's blood sample (such as a plasma, serum, or whole blood sample) that are associated with the Alzheimer's Disease (AD), diagnostic and treatment methods for AD, and kits for diagnosing AD.

阻断神经退行性疾病中的ITGB8

NºPublicación:  CN120476140A 12/08/2025
Solicitante: 
布里格姆妇女医院有限公司加利福尼亚大学董事会
CN_120476140_A

Resumen de: AU2023351193A1

Provided herein are methods and compositions that block Integrin Subunit beta 8 (ITGB8, also known as integrin αvβ8) to treat neurodegenerative diseases associated with microglial impairment including Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS).

制备检测阿尔茨海默病生物标志物的生物传感器的方法及由其制得的生物传感器

NºPublicación:  CN120457337A 08/08/2025
Solicitante: 
长典生物晶片股份有限公司
CN_120457337_A

Resumen de: TW202438878A

The present disclosure provides a method of manufacturing a biosensor for detecting a biomarker of Alzheimer's disease, comprising steps of depositing an aluminum oxide film on a Si substrate by an atomic layer deposition system to form an Al2O3/Si substrate; depositing electrical contacts Cr/Au on the Al2O3/Si substrate by a thermal evaporator to form a source, a drain and a planar gate on the Al2O3/Si substrate; providing a bilayer graphene on the Al2O3/Si substrate by thermal annealing under a vacuum environment; providing a bilayer graphene to a low-damage plasma treatment (LDPT) with a mixture of oxygen and hydrogen to form a graphene oxide/graphene (GO/G) layered composite on the Al2O3/Si substrate; and immobilizing an antibody on a surface of the GO/G layered composite through a reaction between amine groups of the antibody and carboxyl groups of GO of the GO/G layered composites, wherein the antibody is specific for p-tau217 protein.

METHOD FOR EVALUATING ACTIVITY OF INHIBITING OR PROMOTING AGGREGATION OF AGGREGATING PROTEINS

NºPublicación:  US2025250539A1 07/08/2025
Solicitante: 
KANEKA CORP [JP]
KANEKA CORPORATION
US_2025250539_PA

Resumen de: US2025250539A1

A method for evaluating activity of a test substance for inhibiting or promoting aggregation of aggregating proteins is provided. The method includes culturing cells in the presence of aggregating proteins labeled with a label and a test substance, thereby forming a cell culture and quantifying aggregated and/or deposited aggregating proteins on a surface of the cells and/or in the cells in the cell culture with the use of the label as an indicator.

MONOCLONAL ANTIBODY COMPOSITION FOR QUANTITATIVE DETECTION OF AMYLOID IN HUMAN BODY FLUID AND USES

NºPublicación:  US2025251407A1 07/08/2025
Solicitante: 
BEIJING JIAOTONG UNIV [CN]
BEIJING JIAOTONG UNIVERSITY
WO_2024260265_PA

Resumen de: US2025251407A1

A monoclonal antibody composition comprises a capture antibody AB7G and a detection antibody AB11A2 for using in preparation of a kit for quantitative detection of amyloid in human body fluids, and the antibodies are monoclonal antibodies secreted by cultured hybridoma cells. The kit specifically recognizes an Aβ42 oligomer, with a linear detection range of 3.9-125 pg/mL, and a lowest detection limit of 7.8 pg/mL. A core technique for kit assembly lies in that the monoclonal antibody AB7G is fixed on a microplate to serve as the capture antibody, and the monoclonal antibody AB11A2 is labeled and then diluted at 1:2000 to serve as the detection antibody. Meanwhile, the present invention relates to heavy and light chain variable region genes of the monoclonal antibodies AB7G and AB11A2 and peptides encoded thereby.

BIOMOLECULES IN DISEASE

NºPublicación:  EP4595061A1 06/08/2025
Solicitante: 
IMPERIAL COLLEGE INNOVATIONS LTD [GB]
IMPERIAL COLLEGE INNOVATIONS LIMITED
WO_2024069193_A1

Resumen de: WO2024069193A1

The invention relates to methods of screening for the presence of proteopathies, to methods of diagnosing proteopathies, to methods of differentially diagnosing proteopathies, to methods of assessing the severity, stage and/or prognosis of proteopathies, and to methods for monitoring the progression of proteopathies. The invention also relates to methods for determining the efficacy of therapeutic interventions for proteopathies.

BLOCKING ITGB8 IN NEURODEGENERATIVE DISEASE

NºPublicación:  EP4594357A2 06/08/2025
Solicitante: 
BRIGHAM & WOMENS HOSPITAL INC [US]
THE REGENTS OF UNIV OF CALIFORNIA [US]
The Brigham & Women's Hospital, Inc,
The Regents of University of California
AU_2023351193_A1

Resumen de: AU2023351193A1

Provided herein are methods and compositions that block Integrin Subunit beta 8 (ITGB8, also known as integrin αvβ8) to treat neurodegenerative diseases associated with microglial impairment including Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS).

METHOD FOR ASSESSING COAGULATION INHIBITION ACTIVITY OR COAGULATION PROMOTION ACTIVITY AGAINST COAGULATIVE PROTEIN

NºPublicación:  EP4597103A1 06/08/2025
Solicitante: 
KANEKA CORP [JP]
Kaneka Corporation
EP_4597103_A1

Resumen de: EP4597103A1

The objective of the present invention is to provide a method for screening for a substance having activity of inhibiting or promoting aggregation of aggregating proteins. More specifically, the present invention relates to a method for evaluating activity of a test substance for inhibiting or promoting aggregation of aggregating proteins comprising: a step of culturing cells in the presence of aggregating proteins labeled with a label and a test substance; and a step of quantifying the aggregated and/or deposited aggregating proteins on the cell surface and/or in the cells in the cell culture product with the use of the label as the indicator.

ANTI-AMYLOID β PROTOFIBRIL/OLIGOMER ANTIBODIES AND USES THEREOF

NºPublicación:  MX2025008034A 01/08/2025
Solicitante: 
MABWELL THERAPEUTICS INC [US]
MABWELL THERAPEUTICS, INC
MX_2025008034_A

Resumen de: MX2025008034A

The present disclosure provides anti-amyloid β (Aβ) antibodies and antibody fragments that preferentially bind soluble amyloid Aβ protofibril/oligomer and trigger ADPC in microglial cells, anti-amyloid β (Aβ) antibodies and antibody fragments that reduce soluble amyloid Aβ protofibril/oligomer levels and insoluble amyloid Aβ plaque in brain tissue, and the use of anti-Aβ protofibril/oligomer antibodies and antibody fragments in therapy, prophylaxis, diagnosis, screening, and monitoring of conditions associated with Aβ protein aggregation, in particular Alzheimer's disease (AD).

VACCINE COMPOSITION COMPRISING PORPHYROMONAS GINGIVALIS FOR PREVENTING DEMENTIA, AND PREPARATION METHOD THEREFOR

NºPublicación:  WO2025159608A1 31/07/2025
Solicitante: 
UIF UNIV INDUSTRY FOUNDATION YONSEI UNIV [KR]
\uC5F0\uC138\uB300\uD559\uAD50 \uC0B0\uD559\uD611\uB825\uB2E8
WO_2025159608_PA

Resumen de: WO2025159608A1

The present invention relates to the identification of a target material through which Porphyromonas gingivalis affects dementia, and a use of a Porphyromonas gingivalis vaccine for preventing or treating dementia. A composition comprising (Porphyromonas gingivalis, of the present invention, reduces the expression of IGFBP2, Aß and p-Tau and reduces the level of blood insulin, and thus can be used as an effective composition for a dementia vaccine or a composition for preventing, alleviating or treating dementia, and can be effectively used in a method for preventing or treating dementia.

METHODS AND KITS FOR ASSESSING ALZHEIMER'S DISEASE

NºPublicación:  US2025244342A1 31/07/2025
Solicitante: 
MESO SCALE TECH LLC [US]
THE GENERAL HOSPITAL CORP [US]
MESO SCALE TECHNOLOGIES, LLC,
THE GENERAL HOSPITAL CORPORATION
WO_2023196927_PA

Resumen de: US2025244342A1

The disclosure relates to methods and kits for detecting tau, e.g., tau that is phosphorylated at amino acid position T181 (pTau181), tau that is phosphorylated at amino acid position T217 (pTau217), and/or total tau. The disclosure further provides methods for distinguishing between individuals whose cognitive condition will remain stable and whose cognitive condition will decline during their lifetime. The disclosure also provides methods for determining the eligibility of individuals for participation in clinical trials for Alzheimer's disease treatments. Also provided are methods for distinguishing between individuals with Alzheimer's disease and non-Alzheimer's dementia, and for monitoring response to treatment for Alzheimer's disease.

USE OF DISCOIDIN DOMAIN RECEPTOR 2 IN DIAGNOSIS OF NEURODEGENERATIVE DISEASES, AND RELATED COMPUTER READABLE MEDIUM

NºPublicación:  EP4592679A1 30/07/2025
Solicitante: 
FIBROINOVA BIOMEDICAL TECH GUANGZHOU COMPANY LTD [CN]
Fibroinova Biomedical Technology (Guangzhou) Company, Ltd
EP_4592679_PA

Resumen de: EP4592679A1

The present invention discloses use of an agent for detecting the expression level of discoidin domain receptor 2 (DDR2) in the preparation of a kit for diagnosing a neurodegenerative disease in a subject, wherein the level of DDR2 in a sample from the subject being higher than the level of a control not having the disease indicates that the subject has the neurodegenerative disease. The present invention also discloses a kit and a method for diagnosing a neurodegenerative disease, and a computer-readable storage medium. The present invention can efficiently and accurately diagnose the neurodegenerative disease by detecting DDR2.

METHODS OF REDUCING NEURODEGENERATION ASSOCIATED WITH NEURODEGENERATIVE DISEASES

NºPublicación:  EP4590304A1 30/07/2025
Solicitante: 
EISAI R&D MAN CO LTD [JP]
WASHINGTON UNIVERSITY ST LOUIS [US]
Eisai R&D Management Co., Ltd,
Washington University
MX_2025003197_A

Resumen de: MX2025003197A

The disclosure relates to lemborexant, a dual orexin receptor antagonist, and compositions and methods for use in treatment of Alzheimer's disease (AD), e.g., in a subject who has AD or who is at risk for developing AD.

타우(TAU) PET 수준을 이용하는 치료 방법

NºPublicación:  KR20250114372A 29/07/2025
Solicitante: 
에자이알앤드디매니지먼트가부시키가이샤
KR_20250114372_PA

Resumen de: MX2025005880A

Disclosed herein are methods of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD or another disorder associated with amyloid accumulation in the brain using a tau PET level.

アルツハイマー病の治療および/または遅延製品の製造におけるIL-27タンパク質の使用

NºPublicación:  JP2025524284A 28/07/2025
Solicitante: 
広東▲キ▼安特博生物科技有限公司
JP_2025524284_PA

Resumen de: TW202502373A

The invention provides application of IL-27 protein in preparation of a product for treating Alzheimer's disease, and belongs to the technical field of biological medicine. The IL-27 protein is a recombinant IL-27 protein, and aims at a treatment target IL-27, and comprises a mouse source IL-27, a human source IL-27, and a mammal IL-27 except the mouse source IL-27 and the human source IL-27. The recombinant IL-27 protein provided by the invention can effectively relieve Alzheimer's disease caused by A beta deposition, and can be selectively and specifically combined with a receptor of the recombinant IL-27 protein, so that the accuracy of a detection result is ensured; the specificity of the protein receptor is highly expressed in the dentate gyrus region of the sea horse, so that the drug targeting is ensured to the greatest extent; the recombinant IL-27 protein has a good application prospect, can quickly and effectively improve and relieve memory impairment and other behaviors of mice with Alzheimer's disease, and has a clinical transformation value.

MACHINE-LEARNING SYSTEM FOR DIAGNOSING DISORDERS AND DISEASES AND DETERMINING DRUG RESPONSIVENESS

NºPublicación:  US2025238922A1 24/07/2025
Solicitante: 
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST [US]
Sanford Burnham Prebys Medical Discovery Institute
JP_2022535382_A

Resumen de: US2025238922A1

Described are platforms, systems, and methods for screening patients. In one aspect, a computer-implemented method comprises: receiving, from a cellular imaging device, image data comprising calcium kinetic features of neuronal cultures derived from a patient; processing the image data through a machine-learning model to determine a diagnosis for the patient based on the calcium kinetic features, the machine-learning model trained using neuronal calcium data; and providing the diagnosis a user interface.

COMPOSITIONS AND METHODS RELATED TO THE METHYLATION OF HISTONE H1.0 PROTEIN

NºPublicación:  US2025237652A1 24/07/2025
Solicitante: 
AELAN CELL TECH INC [US]
Aelan Cell Technologies, Inc
US_2024255509_PA

Resumen de: US2025237652A1

Provided herein are compositions and methods related to the production and detection of a histone H1.0 protein dimethylated at lysine residue 180 (K180) (H1.0K180me2 protein) or a histone H1.0 peptide dimethylated at a lysine residue corresponding to K180 (H1.0K180me2 peptides). The H1.0K180me2 protein and H1.0K180me2 peptides are useful for applications including, but not limited to, molecular diagnostics of DNA damage, genotoxic stress, radiation exposure, and Alzheimer's disease, therapeutics, monitoring of therapeutic regimens, patient stratification, and drug screening. Also provided herein are antibodies specific for the H1.0K180me2 protein and H1.0K180me2 peptides.

ANTI-RETROVIRAL THERAPIES AND REVERSE TRANSCRIPTASE INHIBITORS FOR TREATMENT OF ALZHEIMER'S DISEASE

Nº publicación: US2025235464A1 24/07/2025

Solicitante:

SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST [US]
Sanford Burnham Prebys Medical Discovery Institute

US_2021267995_A1

Resumen de: US2025235464A1

Described herein are methods for inhibiting generation of one or more non-classical variant(s) of amyloid precursor protein (APP) gene. Provided herein are methods for diagnosing an individual having or suspected of having Alzheimer's disease following identification of an expression profile or an activity profile of the one or more non-classical variant(s) and treating the individual using a reverse transcriptase inhibitor or salt thereof.

traducir